Posted by & filed under Company Analysis, Economic Analysis, Financial analysis, Financial Planning, Governments & Regulators, Growth & Valuation, Industry Analysis, Management Issues, Market Analysis, Personal Finance.

Description: AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.


Date: Jan 28, 2023


Questions for discussion:

  • Summarize the issues related to how businesses, governments, insurance companies and consumers are connected to the drug Humira.
  • Is this an acceptable system for the industry, in your opinion?
  • How might the system be changed in order to be more fair to all parties?

Leave a Reply

Your email address will not be published. Required fields are marked *